Network Pharmacology-Based Investigation of Potential Targets of Astragalus-Angelica Compound Acting on Diabetic Nephropathy
Through network pharmacology and molecular docking to explore the mechanism of astragalus-angelica compound in the treatment of diabetic nephropathy (DN). Screen the components and targets of astragalus and angelica compound on the TCMSP and the BATMAN-TCM, and use Cytoscape 3.7.2 to establish a component-target interaction network. Relevant targets of DN were searched through related databases, and the common targets of astragalus-angelica compound prescription and DN were obtained after comparison. The target protein interaction analysis and visualization processing were performed, and gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analysis were performed through David database, and molecular docking was performed using PyMoL and AutoDock Vina software. Through network pharmacology screening, 142 main targets of astragalus-angelica compound in the treatment of DN have been identified. KEGG pathway enrichment analysis shows that the above key targets are related to apoptosis, oxidative stress, inflammation, insulin resistance and other related pathways. Molecular docking shows that the target protein has a good combination with the main active ingredients of astragalus-angelica compound. Astragalus-angelica compound may act on VEGFA, TP53, IL-6, TNF, mark1 and other targets to treat DN by regulating apoptosis, oxidative stress, inflammation, glucose and lipid metabolism and other pathways. Research methods based on network pharmacology and molecular docking provide new ideas for the pathogenesis and treatment of DN.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Posted 11 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
Network Pharmacology-Based Investigation of Potential Targets of Astragalus-Angelica Compound Acting on Diabetic Nephropathy
Posted 11 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
Through network pharmacology and molecular docking to explore the mechanism of astragalus-angelica compound in the treatment of diabetic nephropathy (DN). Screen the components and targets of astragalus and angelica compound on the TCMSP and the BATMAN-TCM, and use Cytoscape 3.7.2 to establish a component-target interaction network. Relevant targets of DN were searched through related databases, and the common targets of astragalus-angelica compound prescription and DN were obtained after comparison. The target protein interaction analysis and visualization processing were performed, and gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analysis were performed through David database, and molecular docking was performed using PyMoL and AutoDock Vina software. Through network pharmacology screening, 142 main targets of astragalus-angelica compound in the treatment of DN have been identified. KEGG pathway enrichment analysis shows that the above key targets are related to apoptosis, oxidative stress, inflammation, insulin resistance and other related pathways. Molecular docking shows that the target protein has a good combination with the main active ingredients of astragalus-angelica compound. Astragalus-angelica compound may act on VEGFA, TP53, IL-6, TNF, mark1 and other targets to treat DN by regulating apoptosis, oxidative stress, inflammation, glucose and lipid metabolism and other pathways. Research methods based on network pharmacology and molecular docking provide new ideas for the pathogenesis and treatment of DN.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9